Adjuvant Chemotherapy With or Without Intercalated Icotinib
Status:
Not yet recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with
non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine
kinase inhibitors (EGFR-TKI) confers a significant survival benefit. This study aims to
assess the efficacy and safety of adjuvant chemotherapy with or without Intercalated
combination of icotinib in patients undergoing resection of stage IIB to IIIA (N1-2)
EGFR-mutated NSCLC.